Stroke guidelines should be re-written to remove recent use of a DOAC as a contraindication to thrombolysis, Australian neurologists say. Dr Geoffrey Herkes and Dr Chee Hoou Loh make the recommendation in their report of a patient who underwent successful thrombolysis for acute ischaemic stroke after rapid reversal of dabigatran with idarucizumab (Praxbind). The 77-year ...
Already a member?
Enter your email to keep reading.